COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,386 Articles (22,816 medRxiv, 8,570 bioRxiv)

Most recent first Previous |  Page 964: Articles 9631-9640  | Next

COVID-19 Vaccination is Associated with Decreasing Cases, Hospitalizations, and Deaths Across Age Groups and Variants over 9 months in Switzerland
Jucker, J.-L.
10.1101/2022.02.03.22270396 — Posted: 2022-02-03
Device-assessed sleep and physical activity in individuals recovering from a hospital admission for COVID-19: a prospective, multicentre study
Plekhanova, T., Rowlands, A. V., Evans, R. A., Edwardson, C. L., Bishop, N. C., Bolton, C. E., Chalmers, J. D., Davies, M. J., Daynes, E., Docherty, A. B., Elneima, O., Greening, N. J., Greenwood, S. A., Hall, A. P., Harris, V. C., Harrison, E. M., Henson, J., Ho, L.-P., Horsley, A., Houchen-Wolloff, L., Khunti, K., Leavy, O. C., Lone, N. I., Marks, M., Maylor, B., McAuley, H. J. C., Nolan, C. M., Poinasamy, K., Quint, J. K., Raman, B., Richardson, M., Sargeant, J. A., Saunders, R. M., Sereno, M., Shikotra, A., Singapuri, A., Steiner, M., Stensel, D. J., Wain, L. V., Whitney, J., Wootton, D. G., Brightling, C. E., Man, W. D.-C., Singh, S. J., Yates, T.
10.1101/2022.02.03.22270391 — Posted: 2022-02-03
BNT162b2, mRNA-1273, and Sputnik V vaccines induce comparable immune responses on a par with severe course of COVID-19
Kaznadzey, A., Tutukina, M., Bessonova, T., Kireeva, M., Mazo, I.
10.1101/2022.02.03.21265607 — Posted: 2022-02-03
Impact of SARS-CoV-2 variants on inpatient clinical outcome
Robinson, M. L., Morris, C. P., Betz, J., Zhang, Y., Thieman, D. R., Fall, A., Eldesouki, R. E., Norton, J. M., Gaston, D. C., Forman, M., Luo, C. H., Zeger, S. L., Gupta, A., Garibaldi, B. T., Mostafa, H. H.
10.1101/2022.02.02.22270337 — Posted: 2022-02-03
MACHINE LEARNING IMPACT ASSESSMENT OF CLIMATE FACTORS ON DAILY COVID-19 CASES
Afrifa, S., Ato Essien, F., Appiahene, P., Wiafe, I., Owusuaa Mensah Gyening, R.-M., Opoku, M.
10.1101/2022.02.03.22270399 — Posted: 2022-02-03
Concordance of B and T cell responses to SARS-CoV-2 infection, irrespective of symptoms suggestive of COVID-19.
Osterdahl, M. F., Christakou, E., Hart, D., Harris, F., Shahrabi, Y., Pollock, E., Wadud, M., Spector, T. D., Brown, M. A., Seow, J., Malim, M. H., Steves, C. J., Doores, K. J., Duncan, E. L., Tree, T.
10.1101/2022.02.03.22270393 — Posted: 2022-02-03
At-Home Testing Study to Assess Risk Factors for Acquisition of SARS-CoV-2 Infection in a Major US Metropolitan Area
Woolley, A. E., Dryden-Peterson, S., Kim, A., Naz-McLean, S., Kelly, C., Laibinis, H. H., Bagnall, J., Livny, J., Ma, P., Orzechowski, M., Shoresh, N., Gabriel, S., Hung, D. T., Cosimi, L. A.
10.1101/2022.02.02.22269258 — Posted: 2022-02-03
SARS-CoV-2 Omicron variant, lineage BA.1, is associated with lower viral load in nasopharyngeal samples compared to Delta variant.
Sentis, C., Billaud, G., Bal, A., Frobert, E., Bouscambert, M., Destras, G., Josset, L., Lina, B., Morfin, F., Gaymard, A., COVID-Diagnosis HCL Study Group
10.1101/2022.02.02.22269653 — Posted: 2022-02-03 Discussion: Onsite
Private Equity Acquisition in Ophthalmology and Optometry: A Time Series Analysis of the Pre-COVID, COVID Pre-Vaccine, and COVID Post-Vaccine Eras
Patil, S. A., Vail, D. G., Cox, J. T., Chen, E. M., Mruthyunjaya, P., Tsai, J. C., Parikh, R.
10.1101/2022.02.03.22270390 — Posted: 2022-02-03
Unraveling the Enzymatic Mechanism of the SARS-CoV-2 RNA-Dependent-RNA-Polymerase. An Unusual Active Site Leading to High Replication Rates.
Bignon, E., Monari, A.
10.1101/2022.02.02.478873 — Posted: 2022-02-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).